CytoDyn (OTCMKTS:CYDY – Get Free Report) is projected to release its Q4 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties may visit the the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.
CytoDyn Trading Down 1.0%
CYDY stock opened at $0.20 on Wednesday. The stock has a 50-day moving average price of $0.28 and a 200-day moving average price of $0.28. CytoDyn has a 1-year low of $0.20 and a 1-year high of $0.40. The firm has a market cap of $279.58 million, a PE ratio of -6.77 and a beta of 1.16.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Further Reading
- Five stocks we like better than CytoDyn
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
